Using a modified herpes virus to treat brain tumors in children
Official title: Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas
Funded at Treovir, INC · NIH-10244948 · Data updated 2026-11-12
This study is testing a special virus treatment for kids aged 3-18 with tough brain tumors, hoping to see if it can help them live longer and feel better when combined with radiation therapy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Treovir, INC NIH-funded |
| Lab location | 1 site (Birmingham, UNITED STATES) |
| Project start | September 1, 2020 |
| Project end | November 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $890,765 |
| NIH project number | 5R44CA250883-03 |
| Project ID | NIH-10244948 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 3-18 diagnosed with recurrent or progressive high-grade gliomas.
✕Less likely to help
Patients with low-grade gliomas or those who are not experiencing tumor recurrence may not benefit from this research.
What this research studies
This research investigates the use of a specially modified herpes simplex virus (G207) to treat children aged 3-18 who have recurrent or progressive high-grade gliomas, a type of brain tumor. The trial aims to assess the effectiveness and safety of this treatment, which has shown promising results in earlier studies. Participants will receive the virus through direct infusion into the tumor, potentially in combination with radiation therapy. The study builds on previous findings that suggest this approach may improve survival rates in affected children.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for children suffering from aggressive brain tumors.
How similar studies have gone: Previous studies using similar approaches have shown promising results, indicating potential for success in this trial.
Where this research is happening
-
Treovir, INC
Birmingham, United States Active
Researchers
- Principal investigator: Gillespie, George Yancey — Treovir, INC
- Study coordinator: Gillespie, George Yancey
Related research
Other NIH-funded projects on the same topics.
-
MT-125: a brain-penetrant treatment to slow glioblastoma spread and growth
A new drug, MT-125, taken by people with recurrent glioblastoma, targets two motor proteins to slow cancer spread and growth inside the brain.
-
How immune myeloid cells affect aggressive childhood brain tumors
Researchers are looking at whether immune cells called macrophages and neutrophils inside and around aggressive childhood brain tumors are linked to tumor behavior and survival in children with high-grade gliomas.
-
MT-125 treatment for recurrent high-grade brain tumors
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
-
Investigating the role of immune cells in childhood brain tumors
This study is looking at how certain immune cells in the brain, called macrophages and neutrophils, affect a type of brain cancer in kids, and it hopes to find new ways to help treat these young patients better.
-
Understanding how a specific histone mutation affects brain tumor development in children
This study is looking at how a specific change in a gene related to brain development might lead to brain tumors in kids, with the hope that understanding this could help find better treatments for these tough-to-treat tumors.
-
Developing mRNA therapies for a deadly pediatric brain tumor
This study is exploring a new way to treat a tough brain tumor called diffuse midline glioma in kids by using special particles to deliver gene therapy directly to the tumor, aiming to improve how we fight this disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.